Investor Relations Contacts

Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration

Patrick Till
Senior Director
Investor Relations & Corporate Communications

Title	Documents
2020 Form 10-K	Add Files 2020 Form 10-K 1 MB
2019 Form 10-K	Add Files 2019 Form 10-K 644.8 KB
2018 Form 10-K	Add Files 2018 Form 10-K 1.1 MB
2017 Form 10-K	Add Files 2017 Form 10-K 2.4 MB
2016 Form 10-K	Add Files 2016 Form 10-K 1.1 MB
2015 Form 10-K	Add Files 2015 Form 10-K 1.5 MB
2014 Form 10-K	Add Files 2014 Form 10-K 1.5 MB
2013 Form 10-K	Add Files 2013 Form 10-K 1.2 MB
2012 Form 10-K	Add Files 2012 Form 10-K 1.2 MB
2011 Form 10-K	Add Files 2011 Form 10-K 705 KB
2010 Form 10-K	Add Files 2010 Form 10-K 783.2 KB
2009 Form 10-K/A; Amendment No. 2	Add Files 2009 Form 10-K/A; Amendment No. 2 759.6 KB
2009 Form 10-K/A; Amendment No. 1	Add Files 2009 Form 10-K/A; Amendment No. 1 388 KB
2009 Form 10-K	Add Files 2009 Form 10-K 2 MB

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Investor Relations Contacts

Annual Reports

2020 Form 10-K

2019 Form 10-K

2018 Form 10-K

2017 Form 10-K

2016 Form 10-K

2015 Form 10-K

2014 Form 10-K

2013 Form 10-K

2012 Form 10-K

2011 Form 10-K

2010 Form 10-K

2009 Form 10-K/A; Amendment No. 2

2009 Form 10-K/A; Amendment No. 1

2009 Form 10-K

About us

Our Pipeline